Kymera Therapeutics Inc

2026-10-13 20:01; UTC

Kymera Therapeutics Inc shares are declining, diverging from recent gains, amid high trading volume and broader weakness in the biotechnology sector.

2026-10-09 20:07; UTC

Raymond James initiated coverage on Kymera Therapeutics Inc with an Outperform rating and set a price target of $140.

2026-10-08 20:07; UTC

Kymera Therapeutics Inc shares are modestly higher, recovering from a notable low earlier in the day, but remain below their 20-day moving average.

2026-10-07 20:12; UTC

Kymera Therapeutics Inc is trading lower during after-market hours, reflecting a cumulative return of -1.14% since Wednesday's close and remaining below its 20-day moving average.

2026-10-06 20:00; UTC

Kymera Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, amid unusually high trading volume.

2026-10-05 19:51; UTC

Kymera Therapeutics shares rise as Citigroup maintains a Buy rating and raises the price target to $150, reflecting confidence in growth potential.

2026-10-02 20:01; UTC

Kymera Therapeutics Inc. shares fell sharply amid significant insider transactions, including CEO Nello Mainolfi's sale of 30k shares, reflecting ongoing weakness.

2026-10-01 19:45; UTC

Kymera Therapeutics Inc shares fell modestly, currently below the 20-day moving average and near the lower end of its one-month trading range.

2026-09-30 20:03; UTC

Kymera Therapeutics Inc is advancing today with increased trading volume, despite earlier pulling back from a session high, amid broader market gains since Tuesday.

2026-09-29 21:01; UTC

Kymera Therapeutics Inc is seeing higher after-market trading, shifting from a slight loss to a notable gain amid broader market trends and rising bond yields.

2026-09-28 20:01; UTC

Kymera Therapeutics Inc is seeing increased trading activity today, reaching a peak return since Friday, despite remaining below its 20-day moving average.

2026-09-25 20:07; UTC

Kymera Therapeutics Inc shares fell amid a broader market decline, reflecting significant weakness in the biotechnology sector and sympathy with Hyperliquid Strategies Inc.

2026-09-24 20:07; UTC

Kymera Therapeutics Inc's shares are modestly higher, rebounding to close above Wednesday's level despite remaining below its 20-day moving average.

2026-09-23 20:02; UTC

Kymera Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes amid unusually high trading volume.

2026-09-22 20:07; UTC

Stifel reiterated its Buy rating on Kymera Therapeutics and raised the price target to $152, with shares trading higher amid strong momentum.

2026-09-18 20:06; UTC

Kymera Therapeutics Inc shares fell sharply, pulling back from Thursday's close and reaching a low in late afternoon trading after a brief rise earlier in the session.

2026-09-17 20:07; UTC

Kymera Therapeutics Inc is advancing during Thursday's market session, having reached a session high earlier before pulling back from that peak.

2026-09-16 20:10; UTC

Kymera Therapeutics Inc is trading higher as interest grows due to faster-than-expected enrollment in the Phase 2b BROADEN2 study for its drug KT-621.

2026-09-15 23:31; UTC

Kymera Therapeutics Inc shares are lower in after-market hours, continuing a four-session decline amid broader economic concerns from the NY Empire State Manufacturing Index drop.

2026-09-11 19:52; UTC

Kymera Therapeutics Inc is lower today, pulling back from earlier gains amid speculation about Federal Reserve interest rate hikes and broader market trends.

2026-09-10 20:07; UTC

Wolfe Research upgraded Kymera Therapeutics to Outperform, setting a price target of $180. Shares are trading higher amid increased investor interest.

2026-09-09 20:07; UTC

Kymera Therapeutics Inc shares are lower Wednesday, reflecting broader market pressures amid rising crude oil prices and inflation concerns.

2026-09-08 20:07; UTC

Kymera Therapeutics shares are lower amid insider selling, including a recent sale by Brian Adams. The stock has seen a cumulative decline since Friday.

2026-09-02 19:46; UTC

Shares rise as JPMorgan raises price target to $140.00.

2026-08-28 20:01; UTC

Kymera Therapeutics Inc shares are lower today, continuing a decline since Thursday. Trading volume is unusually high amid rising U.S. Treasury yields.

2026-08-27 20:02; UTC

Kymera Therapeutics Inc shares are lower today, diverging from recent gains amid high trading volume and broader market resilience following a drop in jobless claims.

2026-08-25 20:07; UTC

Kymera Therapeutics shares are higher today, supported by declining oil prices and lower Treasury yields, enhancing overall investor sentiment toward equities.

2026-08-21 19:26; UTC

Kymera Therapeutics Inc shares are lower during Friday's session despite earlier gains. Analysts maintain a consensus "Moderate Buy" rating with a target of $125.65.

2026-08-20 22:01; UTC

Kymera Therapeutics Inc. shares are higher in after-market trading, supported by a broader upward trend in biotechnology stocks. The price remains above its 20-day moving average.

2026-08-19 20:02; UTC

Kymera Therapeutics is rising amid gains in the ARK Genomic Revolution ETF, which increased significantly. The stock is also experiencing high market volume today.